Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 11/2022 | Rezo | Series A | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 2/2018 | Kallyope | Series B | 66M |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 1/2022 | Avalo | Convertible Note | 750k |
| 6/2022 | Dren Bio | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 4/2021 | SeQure DX | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2021 | Encodia | Series C | 75M |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 9/2022 | Novome | Series B | 0 |
| 7/2021 | Wugen | Series B | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 5/2022 | Pleno | Seed Round | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 8/2021 | Humacyte | PIPE | 175M |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 5/2021 | Inari | Series D | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 9/2021 | Kytopen | Series A | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 4/2023 | Function Oncology | Series A | 28M |
| 9/2020 | Korro Bio | Series A | 0 |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 12/2018 | Kallyope | Series B | 21M |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 8/2018 | Inari | Series B | 40M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 12/2020 | Faze Medicines | Series A | 81M |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 3/2019 | Gencove | Seed Round | 3M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 7/2021 | Deep Genomics | Series C | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 3/2017 | Boragen | Series A | 10M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 3/2017 | EGenesis | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 12/2022 | SonoThera | Series A | 0 |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 10/2017 | Visterra | Series C | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 6/2018 | StrideBio | Series A | 15.7M |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 10/2017 | Cydan | Venture Round | 34M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 7/2021 | IgGenix | Series A | 0 |
| 9/2018 | OncoResponse | Series B | 40M |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 6/2020 | Element Biosciences | Series B | 30M |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2017 | Halio | Series C | 65M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 11/2019 | Genetron Health | Series D | 71M |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 4/2018 | QurAlis | Seed Round | - |
| 5/2021 | Marvin | Seed Round | 0 |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 11/2018 | Ribometrix | Series A | 30M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 6/2018 | Cibus | Series C | 70M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 4/2019 | Insitro | Series A | 100M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 10/2020 | Dren Bio | Series A | 0 |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 1/2023 | Ensoma | Series B | 0 |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 1/2022 | Korro Bio | Series B | 0 |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2022 | Dantari | Series A | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Benson Hill | Series C | 65M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
